1. Start with your goals, not the platform’s features
Before talking to a single vendor, define what success looks like in measurable terms. Typical priorities include diversifying participant cohorts, compressing time-to-enrollment, and improving site matching precision for complex protocols. Translate those priorities into KPIs so you can benchmark platforms and validate ROI in a pilot. Without this clarity, vendor demos will dazzle rather than inform.
2. Core AI capabilities to evaluate
Look for platforms that address the specific bottlenecks where trials actually lose time:
Patient recruitment & matching. Natural language processing (NLP) to parse unstructured sources (clinical notes, pathology, radiology) for eligibility and risk signals is a critical differentiator. Some tools apply NLP to EHR notes and reports to accelerate patient recruitment significantly.
Predictive analytics. The best AI tools cut cycle time in the exact places trials actually slip: protocol feasibility, site selection, patient identification, and ongoing data review.
Real-time data monitoring. AI systems continuously scan for anomalies and unusual patterns that might indicate data quality issues, protocol deviations, or even potential fraud. Advanced AI platforms can save sponsors up to 90 minutes per query on identification and generation, 50 minutes on data changes, and 35 minutes on data input to analysis.
Digital twin simulations. Digital twin trial simulations test design scenarios virtually and de-risk feasibility — a virtual model of patients or cohorts enables rapid what-if analysis without exposing real patients to risk.
3. Regulatory compliance & data privacy are non-negotiable
AI in clinical trials must meet GxP, GDPR, and FDA expectations — no exceptions. Verify regulatory readiness through documented validation processes and audit trails, and understand their data privacy protocols.
Key compliance items to check:
- Data privacy controls (de-identification, pseudonymization, access logs), PHI handling, GDPR/data residency support, federated learning or on-premise options, role-based access with SSO/MFA, and detailed audit trails.
- The FDA has been proactive in embracing AI's potential while maintaining patient safety commitments — since 2016, they've received approximately 300 submissions referencing AI use, and have issued comprehensive guidance on using AI and machine learning in drug development.
4. Integration with your data environment
A platform is only as good as the data it can access. Inventory what you can actually use — EHR/EMR, claims, disease registries, lab systems, site-level logs, and real-world data (RWD). Best practice is patient metering and de-identified EHR analytics to forecast eligible-patient counts at the site level.
If your data can't easily move, look for vendors who support privacy-preserving analytics like federated learning approaches.
5. Proven cross-functional expertise
Look for cross-functional expertise: data scientists, AI/ML engineers, clinicians, and regulatory experts working together. Understand the team's depth of experience. A platform built by technologists alone — without clinical domain knowledge — tends to solve the wrong problems.
6. Explainability & transparency
You need to understand why the AI is making a recommendation, especially in a regulated environment. Look for vendors who can clearly document their models' intended use, performance bounds, and monitoring approaches, and who align with frameworks like SPIRIT-AI or CONSORT-AI.
7. Agentic capabilities are a must
Static AI that simply surfaces insights is no longer sufficient — the platforms worth investing in today are agentic, meaning they can plan, reason, and act autonomously across multi-step workflows without requiring constant human intervention. In a clinical trial context, this means the platform should be able to do things like automatically flag a site falling behind on enrollment and trigger a corrective workflow, draft a query response, update a risk dashboard, and notify the relevant team member — all as a connected sequence of actions, not isolated alerts. Look for platforms that support AI agents capable of operating across systems (EHR, EDC, CTMS, eCOA) with defined guardrails and human-in-the-loop checkpoints for high-stakes decisions.
The most mature implementations allow sponsors and CROs to configure agents for specific roles — a site performance agent, a data quality agent, a regulatory readiness agent — each operating continuously in the background. As trials grow in complexity and decentralization, agentic AI shifts the model from "AI that helps people work" to "AI that does the work, with people overseeing it." Any platform that lacks a clear agentic roadmap is already behind.
8. Consider running a scoped pilot before committing
Execute a small, 6–12 week pilot. Real-world reporting indicates platforms can identify protocol-eligible patients roughly three times faster with accuracy around 93% — a useful directional benchmark. Decide go/no-go criteria up front (e.g., ≥25% faster shortlisting with no loss of accuracy), and measure timelines, accuracy, and user adoption.
9. Long-term partnerships trump one-off vendors
Look for a long-term collaborator, not a one-off vendor. Working with a collaborator allows for growth benefiting both sides. AI is rapidly evolving, and a one-off vendor may not focus on delivering ongoing improvements.
Quick Evaluation Checklist
What to Ask
AI capabilities
Does it cover recruitment, site selection, data monitoring, and feasibility?
Compliance
GxP, HIPAA, GDPR validated? Audit trails documented?
Data integration
EHR, RWD, claims compatible? Federated options available?
Explainability
Can the AI explain its recommendations?
Team expertise
Clinicians + data scientists + regulatory experts?
Pilot
Will they run a scoped 6–12 week pilot with defined KPIs?
Roadmap
Do they have a published AI development roadmap?
The platforms most commonly cited for clinical trial AI in 2025–2026 include Medable, Medidata, IQVIA, Saama, Deep 6 AI, and Veeva — each with different strengths across recruitment, analytics, and data management. The right choice depends heavily on your therapeutic area, trial phase, and existing data infrastructure.
